Showing results (61-70 of 141) with videos related to

Sort By:
Pageof 15
Clinical Hematology International|July 25, 2024
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emergeOlivier Decaux, Ronan Garlantézec, Karim Belhadj-Merzoug, et al.
Clinical Hematology International|September 22, 2025
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY StudyTitouan Cazaubiel, Olivier Decaux, Bruno Royer, et al.
Blood|November 25, 2010
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trialPhilippe Moreau, Michel Attal, Brigitte Pégourié, et al.
Blood Advances|March 27, 2026
FDG-PET Medullary Total Tumor Volume Highlights High-Risk Newly Diagnosed Multiple Myeloma Patients in CASSIOPEIA TrialJamet Bastien, Shamimeh Ahrari, Sonja Zweegman, et al.
The New England Journal of Medicine|May 11, 2012
Lenalidomide maintenance after stem-cell transplantation for multiple myelomaMichel Attal, Valerie Lauwers-Cances, Gerald Marit, et al.
Blood|November 4, 2009
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM)Murielle Roussel, Philippe Moreau, Anne Huynh, et al.
Future Oncology (London, England)|May 22, 2023
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myelomaThierry Facon, Shaji K Kumar, Torben Plesner, et al.
Cancer Medicine|March 15, 2025
Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020Laure Vincent, Olivier Decaux, Aurore Perrot, et al.
British Journal of Haematology|January 21, 2017
Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trialJin Lu, Jae H Lee, Shang-Yi Huang, et al.
Immunotherapy|November 24, 2020
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparisonPhilippe Moreau, Benjamin Hebraud, Thierry Facon, et al.
Pageof 15